Document is current
Any future updates will be listed below
-
Authors
Jung, Erik https://orcid.org/0000-0002-5016-8202
Osswald, Matthias
Ratliff, Miriam
Dogan, Helin
Xie, Ruifan
Weil, Sophie
Hoffmann, Dirk C.
Kurz, Felix T.
Kessler, Tobias https://orcid.org/0000-0001-8350-7074
Heiland, Sabine
von Deimling, Andreas https://orcid.org/0000-0002-5863-540X
Sahm, Felix https://orcid.org/0000-0001-5441-1962
Wick, Wolfgang https://orcid.org/0000-0002-6171-634X
Winkler, Frank https://orcid.org/0000-0003-4892-6104
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG, SFB 1389)
Deutsche Forschungsgemeinschaft (DFG, SFB 1389)
Deutsche Forschungsgemeinschaft (DFG, SFB 1389)
Deutsche Forschungsgemeinschaft (DFG, SFB 1389)
Deutsche Forschungsgemeinschaft (DFG, SFB 1389)
Deutsche Forschungsgemeinschaft (DFG, SFB 1389)
Deutsche Forschungsgemeinschaft (DFG, SFB 1389)
Deutsche Forschungsgemeinschaft (DFG, SFB 1389)
- License Information
-
More Information
Article History
Received: 30 June 2020
Accepted: 8 January 2021
First Online: 12 February 2021
Competing interests
: E.J., M.O., W.W. and F.W. report the patent (WO2017020982A1) “Agents for use in the treatment of glioma”. F.W. is co-founder of DC Europa Ltd (a company trading under the name Divide & Conquer) that is developing new medicines for the treatment of glioma. Divide & Conquer also provides research funding to F.W.’s lab under a research collaboration agreement. All other authors declare no competing interests.
